Please Note: Microsoft has ended support of its older browsers as of January 2016. If you are seeing this message, you are viewing the site on an unsupported version of Internet Explorer (IE10 or older). To properly view this website, please upgrade your version of IE or access this site using a different browser. Thank you.
Sign InDues Join Privacy Contact Search
Home News Scrip

Scrip

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below.

John Lezcano
Corporate Account Manager
M: (631) 807-4971
John.lezcano@informa.com

Pharma intelligence | informa
P: (212) 652-2678
pharmaintelligence.informa.com

Scrip
Tuesday, July 7, 2020
Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the...
Tuesday, July 7, 2020
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS...
Tuesday, July 7, 2020
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a...
Tuesday, July 7, 2020
Tuesday, July 7, 2020
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll...
Tuesday, July 7, 2020
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in...
Tuesday, July 7, 2020
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies...
Tuesday, July 7, 2020
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health...
Monday, July 6, 2020
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval...
Monday, July 6, 2020
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but...